Dellarex Biotec Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 15-11-2024
- Paid Up Capital ₹ 3.00 M
as on 15-11-2024
- Company Age 8 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.12 Cr
as on 15-11-2024
- Satisfied Charges ₹ 4.00 M
as on 15-11-2024
- Revenue -12.32%
(FY 2023)
- Profit -57.26%
(FY 2023)
- Ebitda -35.30%
(FY 2023)
- Net Worth 14.83%
(FY 2023)
- Total Assets 64.02%
(FY 2023)
About Dellarex Biotec
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 3.00 M.
The company currently has active open charges totaling ₹2.12 Cr. The company has closed loans amounting to ₹4.00 M, as per Ministry of Corporate Affairs (MCA) records.
Reji Cyriac and Sija Cyriac serve as directors at the Company.
- CIN/LLPIN
U74999MH2016PTC285999
- Company No.
285999
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Sep 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Dellarex Biotec Private Limited offer?
Dellarex Biotec Private Limited offers a wide range of products and services, including Common Disease Medicines, Anaemia Medicine, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Anti Infective Drugs & Medicines, HIV Drugs, Cardiovascular Drugs & Medication, Cardiac Drugs, Anti Cancer Injection, Immunosuppressive Drugs.
Who are the key members and board of directors at Dellarex Biotec?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Reji Cyriac  | Director | 19-Sep-2016 | Current |
| Sija Cyriac | Director | 19-Sep-2016 | Current |
Financial Performance of Dellarex Biotec.
Dellarex Biotec Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 12.32% decrease. The company also saw a substantial fall in profitability, with a 57.26% decrease in profit. The company's net worth Soared by an impressive increase of 14.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dellarex Biotec?
In 2023, Dellarex Biotec had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 29 Jun 2019 | ₹2.12 Cr | Open |
Others Creation Date: 16 Jan 2018 | ₹4.00 M | Satisfied |
How Many Employees Work at Dellarex Biotec?
Unlock and access historical data on people associated with Dellarex Biotec, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dellarex Biotec, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dellarex Biotec's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
